### Efavirenz + emtricitabine + tenofovir

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified a as therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.

- **Indication**: Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
- **INN**: Efavirenz + emtricitabine + tenofovir
- **Medicine type**: Chemical agent
- **List type**: Core
- **Formulations**: Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
- **EML status history**: First added in 2007 (TRS 946), Changed in 2021 (TRS 1035)
- **Sex**: All
- **Age**: Adolescents and adults
- **Therapeutic alternatives**: efavirenz + lamivudine + tenofovir (ATC codes: J05AR11)
- **Patent information**: Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org). Read more about patents.

**ATC codes:** J05AR06

**ICD11 code:** 1C62.Z

**Wikipedia**

[Efavirenz + emtricitabine + tenofovir](https://en.wikipedia.org/wiki/Efavirenz)

**DrugBank**

[Efavirenz](http://www.drugbank.ca/drugs/DB00448), [Emtricitabine](http://www.drugbank.ca/drugs/DB00449), [Tenofovir disoproxil](http://www.drugbank.ca/drugs/DB00446)